Methods of dosing engineered t cells for the treatment of b cell malignancies

Abstract

Abstract Provided are methods for treatment and uses involving the administration of doses of engineered T cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The engineered cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL). In some embodiments, the subject is within a particular range of age, such as subjects that are 25 years or less of age, such as pediatric subjects. Abstract 20 26 21 07 80 30 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 1 0 7 8 0 3 0 J u l 2 0 2 6